SOLARNCT06880055
Shield Post-Approval Study Protocol
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 7 versions: 7 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 22 words
- Trial sites expanded: 69 → 83 locations
- Minor Trial sites expanded: 56 → 69 locationsv6
- Minor Study sites: 43 to 56v5
- Minor Study sites: 1 to 43v4
- Notable Trial status: Not Yet Recruiting to Recruiting
- Eligibility criteria expanded, about 109 words
- Start date changed from estimate of Sep 1, 2025 to Jul 14, 2025
- Minor Study description revisedv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Performance measures of the Shield test will be assessed for the second testing interval
Timeframe: 33-42 Months Post-Enrollment
Arms and interventions
Enrolled Subjects
Subjects age 45 to 81 at average risk of CRC who meet inclusion, do not meet exclusion criteria, and who successfully enroll in the study.
Diagnostic tests: Shield Blood Test for colo-rectal cancer Screening
Sites
83 sites in 1 country